[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"CellinCells\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100629422","phase-1-safety-and-efficacy-of-autologous-adipose-derived-mesenchymal-stem-cells-therapy-in-adults-with-atrophic-scars-100629422",false,"NCT07474467","Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Split-Face, Phase 1\u002F2 Study to Evaluate the Safety and Efficacy of a Single Administration of TRTP-101 in Adults With Atrophic Scars","Inclusion Criteria:\n\n* Male or Female aged greater than 19 years\n* Acne scars graded ≥ 3 on the 5-point ASRS\n\n\\[Phase 1\\]\n\n* Four or more atrophic scars in the joints, genitals, perineum, and face except for the lips, eyes and nose\n\n\\[Phase 2\\]\n\n* Atrophic scar lesions approximately 2 cm in diameter located on the cheeks or temple on both sides of the face\n* A response of \"dissatisfied\" or worse on the Subject Acne Scar Self-Assessment Scale\n\nExclusion Criteria:\n\n* History of cell therapy\n* Treatment of Dermal resurfacing, Chemical\u002FMechanical Peel and Skin Photorejuvenation\n* Treatment of Hyaluronic acid\u002Fcollagen skin filler, non-permanent soft tissue filler and fat grafting\n* Positive for virus infection\n* Use of Anticoagulant therapy or NSAIDs\n* Thrombocytopenia or other coagulation disorder\n* History of keloid scars\n* Infectious disease or other dermatitis in the area of the atrophic scar\n* Use of Immunosuppressant, immunomodulating drug, anticancer drug or radiation therapy\n* Use of systemic steroid medication\n* History of hypersensitivity or severe allergic reactions (e.g., anaphylaxis, Guillain-Barre syndrome, etc.)\n* Use of retinoid medications",true,"ALL","19 Years",{"count":20,"type":21},31,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The purpose of this clinical trial was to evaluate the safety and efficacy of a single administration of TRTP-101 in adults with atrophic scars.",[28],"Atrophic Scar","NOT_YET_RECRUITING","2026-03-11",{"date":32,"type":33},"2026-03-16","ACTUAL",{"date":35,"type":21},"2026-08-01",{"date":37,"type":21},"2029-08-01",{"name":39,"class":40},"CellinCells","INDUSTRY",""]